Patupilone
- Generic Name
- Patupilone
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H41NO6S
- CAS Number
- 152044-54-7
- Unique Ingredient Identifier
- UEC0H0URSE
- Background
Epothilone B is a 16-membered macrolide that mimics the biological effects of taxol.
- Indication
Investigated for use/treatment in ovarian cancer, lung cancer, brain cancer, breast cancer, and gastric cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Patupilone (EPO 906) in Patients With Recurrent or Progressive Glioblastoma
- Conditions
- First Posted Date
- 2008-07-14
- Last Posted Date
- 2011-09-15
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 9
- Registration Number
- NCT00715013
Phase I Study of Patupilone and RAD001
- Conditions
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2012-06-14
- Target Recruit Count
- 42
- Registration Number
- NCT00496600
- Locations
- 🇺🇸
The Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
The Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies
- Conditions
- First Posted Date
- 2007-05-02
- Last Posted Date
- 2009-11-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT00468260
Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies
- First Posted Date
- 2007-03-16
- Last Posted Date
- 2009-11-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 17
- Registration Number
- NCT00448396
Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies (Extension)
- First Posted Date
- 2007-03-02
- Last Posted Date
- 2012-04-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT00442741
Combination Trial of Patupilone and Carboplatin in Adult Patients With Advanced Solid Tumors
- First Posted Date
- 2007-01-25
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT00426582
- Locations
- 🇺🇸
Wertz Clinical Cancer Center (Wayne State University), Detroit, Michigan, United States
🇺🇸Cancer Research and Treatment Center (University of New Mexico), Albuquerque, New Mexico, United States
🇺🇸Norwalk Hospital, Norwalk, Connecticut, United States
Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies.
- First Posted Date
- 2007-01-24
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 5
- Registration Number
- NCT00426140
- Locations
- 🇺🇸
Cancer Therapy and Research Center, Institution for Drug Development, San Antonio, Texas, United States
Efficacy and Safety of Patupilone in Patients With Advanced Solid Tumors in Japan
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2010-05-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 15
- Registration Number
- NCT00412789
- Locations
- 🇯🇵
Novartis Investigative Site, Tokyo, Japan
Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-12-14
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 185
- Registration Number
- NCT00411528
- Locations
- 🇺🇸
University of Colorado Dept. of Univ. of Colorado, Aurora, Colorado, United States
🇺🇸University of California San Diego Dept of Moores Cancer Center, La Jolla, California, United States
🇺🇸Norwalk Hospital, Norwalk, Connecticut, United States
Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel Chemotherapy
- Conditions
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2010-11-05
- Lead Sponsor
- British Columbia Cancer Agency
- Target Recruit Count
- 73
- Registration Number
- NCT00407251
- Locations
- 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.